Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by date.
Page 8: 1 2 3 4 5 6 7 8 9
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
2101 | 12 | 35 | 2057 2002 JUN 15 BLOOD 99(12):4525-4530 Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | 13 | 53 |
2102 | 0 | 0 | 2131 2002 JUN [15] BRITISH JOURNAL OF CANCER 86:S26-S26 Marriott JB; Clarke IA; Dredge K; Pandha H; Kristaleit H; Polychronis A; Muller GW; Stirling D; Dalgleish AG Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation | 3 | 3 |
2103 | 0 | 0 | 2132 2002 JUN [15] BRITISH JOURNAL OF CANCER 86:S42-S42 Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. | 0 | 0 |
2104 | 0 | 0 | 2133 2002 JUN [15] BRITISH JOURNAL OF CANCER 86:S117-S118 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling D; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumour activity in which caspase dependent apoptosis is associated with altered expression of BCL-2 family proteins | 0 | 0 |
2105 | 4 | 6 | 2135 2002 JUN [15] BRITISH JOURNAL OF DERMATOLOGY 146(6):1112-1113 Pouaha J; Martin S; Reichert-Penetrat S; Trechot P; Barbaud A; Schmutz JL Thalidomide and sexual dysfunction in men | 0 | 0 |
2106 | 4 | 5 | 2137 2002 JUN [15] BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997 Bauduer F Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
2107 | 28 | 54 | 2161 2002 JUN [15] CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 13 | 14 |
2108 | 0 | 0 | 2166 2002 JUN [15] CLINICAL IMMUNOLOGY 103(3):S95-S95 Verastegui E; Morales R; Martinez R; Barrera J Immunological effects of thalidomide treatment of cancer patients. | 0 | 0 |
2109 | 61 | 107 | 2169 2002 JUN [15] CROATIAN MEDICAL JOURNAL 43(3):274-285 Mujagic H; Chabner BA; Mujagic Z Mechanisms of action and potential therapeutic uses of thalidomide | 1 | 2 |
2110 | 0 | 0 | 2183 2002 JUN [15] EXPERIMENTAL HEMATOLOGY 30(6):60-60 Biscardi M; Gavazzi S; Balestri F; Grossi A Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2111 | 0 | 0 | 2184 2002 JUN [15] EXPERIMENTAL HEMATOLOGY 30(6):98-98 Mohty M; Blaise D; Isnardon D; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
2112 | 0 | 0 | 2185 2002 JUN [15] EXPERIMENTAL HEMATOLOGY 30(6):98-98 Schey S; Jones R; Raj K; Streetley M A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma | 0 | 0 |
2113 | 11 | 19 | 2218 2002 JUN [15] JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304 Curley MJ; Hussein SA; Hassoun PM Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma | 0 | 0 |
2114 | 4 | 16 | 2249 2002 JUN [15] JOURNAL OF THE CHINESE CHEMICAL SOCIETY 49(3):383-385 Chang MY; Chang CH; Chen ST; Chang NC A synthesis of thalidomide | 0 | 9 |
2115 | 5 | 23 | 2258 2002 JUN [15] LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
2116 | 7 | 17 | 2266 2002 20020629-02:12:34 [JUN 29] MEDICAL ONCOLOGY 19(2):79-86 Merup M; Kutti J; Birgergard G; Mauritzson N; Bjorkholm M; Markevarn B; Malm C; Westin J; Palmblad J; Samuelsson J; Swedish Natl Study Grp Chronic Mye Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | 4 | 5 |
2117 | 3 | 3 | 2024 2002 JUL [15] AMERICAN JOURNAL OF HEMATOLOGY 70(3):265-265 Pulik M; Genet P; Lionnet F; Touahri T Thalidomide-associated gynecomasty in a patient with multiple myeloma | 1 | 1 |
2118 | 7 | 28 | 2030 2002 JUL [15] ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 10 | 21 |
2119 | 3 | 14 | 2031 2002 JUL [15] ANNALS OF ONCOLOGY 13(7):1116-1119 Alexanian R; Weber D; Giralt S; Delasalle K Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy | 6 | 9 |
2120 | 0 | 1 | 2036 2002 JUL [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(7):2313-2313 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis (vol 46, pg 1889, 2002) | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2121 | 4 | 4 | 2138 2002 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347 Myers B; Dolan G Analysis of durability of response to thalidomide treatment for relapsed myeloma patients | 1 | 1 |
2122 | 15 | 29 | 2156 2002 JUL [15] CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 24 |
2123 | 8 | 16 | 2158 2002 JUL-AUG [JUL 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(4):S43-S44 Seyahi E; Ozdogan H; Masatlioglu S; Yazici H Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient | 0 | 4 |
2124 | 9 | 18 | 2186 2002 JUL [15] FARMACO 57(7):551-554 Blaschke G; Meyring M; Muhlenbrock C; Chankvetadze B Recent results of biotransformation of drugs: investigation of the in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 0 | 2 |
2125 | 13 | 38 | 2192 2002 JUL [15] GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 12 |
2126 | 11 | 22 | 2204 2002 JUL [15] INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153 Shannon EJ; Sandoval FG Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant | 4 | 4 |
2127 | 19 | 30 | 2210 2002 JUL [15] INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572 Fu LM; Fu-Liu CS Thalidomide and tuberculosis | 2 | 3 |
2128 | 0 | 0 | 2233 2002 JUL [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(1):212-212 Heere-Ress E; Boehm J; Hoeller C; Thallinger C; Wolff K; Pehamberger H; Jansen B Anti-tumor effect of thalidomide and dacarbazine in melanoma SCID mouse model | 0 | 0 |
2129 | 0 | 1 | 2250 2002 SUM [JUL 15] JOURNAL OF THE HISTORY OF BIOLOGY 35(2):387-389 Keiner C Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
2130 | 0 | 0 | 2269 2002 JUL-AUG [JUL 15] NEUROBIOLOGY OF AGING 23(1):S93-S93 Burke W; Bohac D; Cotter R; Zheng JL; Potter J; Gendelman H A 26 week double blind, placebo-controlled study of the efficacy of thalidomide in the treatment of Alzheimer's disease | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2131 | 11 | 15 | 2285 2002 JUL [15] REVUE DE MEDECINE INTERNE 23(7):651-656 Claudon A; Dietemann JL; De Compte AH; Hassler P Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in Langerhans cell histiocytosis. | 1 | 1 |
2132 | 11 | 26 | 2171 2002 20020717-00:58:03 [JUL 17] DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
2133 | 10 | 22 | 2242 2002 JUL 20 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 29(4):761-766 Liu T; Li MX; Li QY Electrochemical behavior of thalidomide | 0 | 0 |
2134 | 15 | 40 | 2027 2002 AUG 1 ANALYTICAL CHEMISTRY 74(15):3726-3735 Meyring M; Muhlbacher J; Messer K; Kastner-Pustet N; Bringmann G; Mannschreck A; Blaschke G In vitro biotransformation of (R)- and (S)-thalidomide: Application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites | 0 | 2 |
2135 | 1 | 1 | 2225 2002 AUG 1 JOURNAL OF CLINICAL ONCOLOGY 20(15):3361-3361 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial (vol 20, pg 2610, 2002) | 0 | 0 |
2136 | 4 | 23 | 2058 2002 AUG 15 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 17 | 31 |
2137 | 1 | 3 | 2059 2002 AUG 15 BLOOD 100(4):1519-1520 Leleu X; Magro L; Fawaz A; Bauters F; Facon T; Yakoub-Agha I Efficacy of a low dose of thalidomide in advanced multiple myeloma | 7 | 7 |
2138 | 13 | 33 | 2147 2002 AUG 15 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 5 | 10 |
2139 | 1 | 9 | 2162 2002 AUG [15] CLINICAL CANCER RESEARCH 8(8):2750-2750 Go RS; Horstman AL Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. | 0 | 0 |
2140 | 0 | 6 | 2163 2002 AUG [15] CLINICAL CANCER RESEARCH 8(8):2751-2751 Neben K Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2141 | 5 | 25 | 2180 2002 AUG [15] EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460 Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD Effect of thalidomide on the skeletal muscle in experimental heart failure | 1 | 2 |
2142 | 3 | 10 | 2200 2002 AUG [15] HAEMATOLOGICA 87(8):884-886 Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes | 1 | 1 |
2143 | 10 | 15 | 2217 2002 AUG [15] JOURNAL OF CLINICAL GASTROENTEROLOGY 35(2):149-150 Kane S; Stone LJ; Ehrenpreis E Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab - A case series | 3 | 5 |
2144 | 6 | 28 | 2238 2002 AUG [15] JOURNAL OF NUCLEAR MEDICINE 43(8):1084-1089 Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts | 1 | 7 |
2145 | 2 | 32 | 2239 2002 AUG-SEP [AUG 15] JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
2146 | 8 | 15 | 2245 2002 AUG [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(2):S193-S195 Duong DHJ; Moxley RT; Kellman RM; Pincus SH; Gaspari AA Thalidomide therapy for cicatricial pemphigoid | 0 | 0 |
2147 | 14 | 18 | 2281 2002 AUG [15] PHARMACEUTICAL RESEARCH 19(8):1232-1235 Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs | 3 | 3 |
2148 | 11 | 47 | 2282 2002 AUG [15] PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
2149 | 9 | 11 | 2286 2002 AUG [15] REVUE DE MEDECINE INTERNE 23(8):724-727 Gachon J; Grob JJ; Richard MA Thalidomide treatment leading thrombotic events: two cases | 3 | 4 |
2150 | 0 | 0 | 2015 2002 AUG 18 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 224:U21-U21 Hu ZG; Zink J; Zili X; Shi JD; Li PK Anti-angiogenic and anti-proliferative thalidomide analogs. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2151 | 4 | 6 | 2265 2002 SEP 2 MEDICAL JOURNAL OF AUSTRALIA 177(5):278-278 McBride W Thalidomide and cancer | 1 | 1 |
2152 | 0 | 0 | 2251 2002 SEP 4 JOURNAL OF THE NATIONAL CANCER INSTITUTE 94(17):1270-1272 Friedrich MJ Despite checkered past, thalidomide and its analogues show potential | 0 | 0 |
2153 | 94 | 118 | 2151 2002 20020905-05:14:02 [SEP 05] CANCER INVESTIGATION 20(5-6):835-848 Baidas S; Tfayli A; Bhargava P Thalidomide: An old drug with new clinical applications | 1 | 3 |
2154 | 6 | 15 | 2016 2002 SEP [15] ACTA DERMATO-VENEREOLOGICA 82(5):384-386 Kolde G; Schulze P; Sterry W Mixed response to thalidomide therapy in adults: Two cases of multisystem Langerhans' cell histiocytosis | 1 | 2 |
2155 | 0 | 16 | 2021 2002 SEP [15] AMERICAN BIOLOGY TEACHER 64(7):495-500 Seidman LA; Warren NN Frances Kelsey & thalidomide in the US: A case study relating to pharmaceutical regulations | 0 | 0 |
2156 | 0 | 0 | 2023 2002 SEP 15 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 59(18):1700-+ Young D Thalidomide prescribers cannot assign survey responsibility to pharmacists | 0 | 0 |
2157 | 0 | 0 | 2039 2002 SEP [15] ARTHRITIS AND RHEUMATISM 46(9):S290-S290 Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GRV Thalidomide in lupus: Efficacy and toxicity are not dose-dependent. | 0 | 0 |
2158 | 0 | 0 | 2040 2002 SEP [15] ARTHRITIS AND RHEUMATISM 46(9):S480-S481 Schwartz KH; Agle LMA; Lehman TJA Thalidomide therapy of systemic onset JIA: Continued success. | 0 | 2 |
2159 | 4 | 33 | 2050 2002 SEP [15] BIOORGANIC & MEDICINAL CHEMISTRY 10(9):3067-3073 Lima LM; Castro P; Machado AL; Fraga CAM; Lugnier C; de Moraes VLG; Barreiro EJ Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues | 2 | 6 |
2160 | 4 | 20 | 2060 2002 SEP 15 BLOOD 100(6):2263-2265 Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma | 9 | 19 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2161 | 8 | 8 | 2061 2002 SEP 15 BLOOD 100(6):2272-2273 Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy | 11 | 15 |
2162 | 11 | 23 | 2150 2002 SEP [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 1 | 1 |
2163 | 90 | 130 | 2159 2002 SEP-OCT [SEP 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
2164 | 0 | 0 | 2188 2002 SEP [15] FERTILITY AND STERILITY 78(3):S87-S87 Scarpellini F; Sbracia M; Lecchini S; Scarpellini L Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study. | 0 | 1 |
2165 | 14 | 28 | 2212 2002 SEP [15] JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
2166 | 0 | 0 | 2247 2002 SEP [15] JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
2167 | 0 | 0 | 2248 2002 SEP [15] JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
2168 | 11 | 38 | 2254 2002 SEP [15] LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 7 | 12 |
2169 | 7 | 29 | 2259 2002 SEP [15] LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
2170 | 7 | 38 | 2268 2002 SEP [15] MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 7 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2171 | 3 | 5 | 2276 2002 SEP [15] ONCOLOGY-NEW YORK 16(9):1146-+ Leibowitz R; Tucker SJ PSA response to thalidomide in patients with advanced prostate cancer | 0 | 0 |
2172 | 53 | 61 | 2277 2002 SEP [15] ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
2173 | 23 | 35 | 2289 2002 SEP [15] TERATOLOGY 66(3):115-121 Stromland K; Philipson E; Gronlund MA Offspring of male and female parents with thalidomide embryopathy: Birth defects and functional anomalies | 1 | 3 |
2174 | 0 | 0 | 2154 2002 OCT 7 CHEMICAL & ENGINEERING NEWS 80(40):60-60 [Anon] Thalidomide and Frances Kelsey | 0 | 0 |
2175 | 4 | 6 | 2032 2002 OCT [15] ANNALS OF ONCOLOGY 13(10):1636-1640 Grover JK; Uppal G; Raina V The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma | 3 | 4 |
2176 | 18 | 27 | 2037 2002 OCT [15] ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
2177 | 8 | 12 | 2139 2002 OCT [15] BRITISH JOURNAL OF HAEMATOLOGY 119(1):128-130 Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report | 1 | 3 |
2178 | 3 | 5 | 2140 2002 OCT [15] BRITISH JOURNAL OF HAEMATOLOGY 119(1):275-275 Pitini V; Teti D; Arrigo C; Aloi G Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF | 0 | 0 |
2179 | 6 | 43 | 2148 2002 OCT 15 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 14 |
2180 | 33 | 37 | 2157 2002 OCT [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 15 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2181 | 6 | 38 | 2173 2002 OCT [15] DEVELOPMENTAL DYNAMICS 225(2):186-194 Hansen JM; Gong SG; Philbert M; Harris C Misregulation of gene expression in the redox-sensitive NF-kappa B-dependent limb outgrowth pathway by thalidomide | 1 | 2 |
2182 | 5 | 40 | 2213 2002 OCT [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
2183 | 16 | 34 | 2214 2002 OCT [15] JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
2184 | 3 | 5 | 2261 2002 OCT [15] LEUKEMIA RESEARCH 26(10):965-966 Tsirigotis P; Venetis E; Rontogianni D; Dervenoulas J; Kontopidou F; Apostolidis P Thalidomide in the treatment of myelodysplastic syndrome with fibrosis | 2 | 2 |
2185 | 2 | 25 | 2278 2002 OCT [15] PEDIATRIC RESEARCH 52(4):576-579 Narita N; Kato M; Tazoe M; Miyazaki K; Narita M; Okado N Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: Putative animal models for autism | 0 | 3 |
2186 | 0 | 0 | 2283 2002 OCT [15] PHARMACOTHERAPY 22(10):1362-1362 Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetics of thalidomide: drug response, in vivo metabolism and genetic polymorphism of CYP2C19. | 0 | 0 |
2187 | 3 | 18 | 2155 2002 20021016-04:06:50 [OCT 16] CHEMICAL COMMUNICATIONS (19):2242-2243 Augusti DV; Augusti R; Carazza F; Cooks RG Quantitative determination of the enantiomeric composition of thalidomide solutions by electrospray ionization tandem mass spectrometry | 0 | 0 |
2188 | 0 | 0 | 2244 2002 20031024-09:12:41 [OCT 24] JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
2189 | 19 | 36 | 2181 2002 OCT 25 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334 Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide | 1 | 3 |
2190 | 22 | 37 | 2226 2002 NOV 1 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 29 | 52 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2191 | 0 | 0 | 2205 2002 20021102-01:03:26 [NOV 02] INTERNATIONAL JOURNAL OF CANCER :104-104 Hatjiharissi E; Gerotziafas G; Papaioannou M; Bakaloudi V; Tokmaktsis A; Kaloutsi V; Christakis J; Zervas K Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease | 0 | 0 |
2192 | 0 | 0 | 2206 2002 20021102-01:03:26 [NOV 02] INTERNATIONAL JOURNAL OF CANCER :336-337 Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma | 0 | 0 |
2193 | 0 | 0 | 2207 2002 20021102-01:03:26 [NOV 02] INTERNATIONAL JOURNAL OF CANCER :402-402 Hatjiharissi E; Gerotziafas G; Hatjileontis C; Galaktidou G; Bakaloudi V; Papaioannou M; Kaloutsi V; Kortsaris A; Christakis J; Zervas K Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone | 0 | 0 |
2194 | 10 | 36 | 2134 2002 NOV 4 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 9 | 15 |
2195 | 13 | 27 | 2022 2002 NOV [15] AMERICAN HEART JOURNAL 144(5):847-850 Gullestad L; Semb AG; Holt E; Skardal R; Ueland T; Yndestad A; Froland SS; Aukrust P Effect of thalidomide in patients with chronic heart failure | 1 | 4 |
2196 | 12 | 27 | 2026 2002 NOV [15] AMERICAN JOURNAL OF MEDICINE 113(7):603-606 Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W Thalidomide-associated deep vein thrombosis and pulmonary embolism | 3 | 6 |
2197 | 0 | 4 | 2141 2002 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 119(2):576-577 Jones SG; Dolan G; Lengyel K; Myers B Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions | 0 | 2 |
2198 | 9 | 9 | 2143 2002 NOV [15] BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1303-1305 Eter N; Spitznas M DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture | 0 | 0 |
2199 | 1 | 9 | 2144 2002 NOV [15] BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1315-1316 Shuttleworth GN; Cook SD; Ropner JE Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia | 0 | 0 |
2200 | 17 | 29 | 2149 2002 NOV-DEC [NOV 15] CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2201 | 14 | 18 | 2160 2002 NOV-DEC [NOV 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
2202 | 17 | 24 | 2164 2002 NOV [15] CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
2203 | 33 | 53 | 2170 2002 NOV [15] CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 5 | 10 |
2204 | 17 | 34 | 2175 2002 NOV [15] DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
2205 | 0 | 0 | 2177 2002 NOV [15] EUROPEAN JOURNAL OF CANCER 38:S53-S53 Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J Thalidomide modulation of Irinotecan; an NF-kB dependent effect? | 0 | 0 |
2206 | 0 | 0 | 2178 2002 NOV [15] EUROPEAN JOURNAL OF CANCER 38:S82-S82 Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD In vitro antiangiogenic activity of thalidomide analogues | 0 | 0 |
2207 | 13 | 15 | 2203 2002 NOV [15] HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
2208 | 7 | 20 | 2209 2002 NOV [15] INTERNATIONAL JOURNAL OF HEMATOLOGY 76(4):365-369 Miller S; Sharda S; Rodrigue J; Mehta P Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life | 0 | 0 |
2209 | 12 | 19 | 2211 2002 NOV [15] INVESTIGATIONAL NEW DRUGS 20(4):389-393 Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L A phase II study of thalidomide in advanced metastatic renal cell carcinoma | 6 | 9 |
2210 | 7 | 8 | 2234 2002 NOV [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):987-988 Gaspari A Thalidomide neurotoxicity in dermatological patients: The next "STEP'' | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2211 | 20 | 24 | 2235 2002 NOV [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
2212 | 23 | 30 | 2236 2002 NOV [15] JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945 Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide | 2 | 6 |
2213 | 22 | 32 | 2291 2002 NOV-DEC [NOV 15] THERAPIE 57(6):524-529 Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Role of thalidomide with or without dexamethasone for refractory multiple myeloma | 0 | 0 |
2214 | 0 | 0 | 2062 2002 NOV 16 BLOOD 100(11):15B-15B Carneiro JDA; Garanito M; Halsman M; Matsumoto L; Odone V; del Giglio A Thalidomide as salvage therapy for acquired severe aplastice anemia (SAA) in children - Case report | 0 | 0 |
2215 | 0 | 0 | 2063 2002 NOV 16 BLOOD 100(11):71A-71A Mesa RA; Li CY; Steensma DP; Pardanani A; Elliott MA; Kaufmann SH; Gray L; Schroeder GS; Tefferi A A combination of low dose thalidomide with prednisone in myelofibrosis with myeloid metaplasia. | 0 | 0 |
2216 | 0 | 0 | 2064 2002 NOV 16 BLOOD 100(11):75B-75B Kaushal V; Kaushal GP; Anaissie EJ; Kurylo P; Kohli M; Fink LM; Mehta P Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium. | 0 | 0 |
2217 | 0 | 0 | 2065 2002 NOV 16 BLOOD 100(11):96A-96A List AF; Kurtin SE; Glinsmann-Gibson BJ; Bellamy WT; Buresh AJ; Waddleton D; Knight R High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). | 0 | 3 |
2218 | 0 | 0 | 2066 2002 NOV 16 BLOOD 100(11):96A-96A Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). | 0 | 1 |
2219 | 0 | 0 | 2067 2002 NOV 16 BLOOD 100(11):105A-105A Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. | 0 | 5 |
2220 | 0 | 0 | 2068 2002 NOV 16 BLOOD 100(11):139A-139A List AF; Tate W; Glinsmann-Gibson BJ; Baker A The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2221 | 0 | 0 | 2069 2002 NOV 16 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
2222 | 0 | 0 | 2070 2002 NOV 16 BLOOD 100(11):170A-170A Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma. | 0 | 0 |
2223 | 0 | 0 | 2071 2002 NOV 16 BLOOD 100(11):178A-178A Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. | 0 | 0 |
2224 | 0 | 0 | 2072 2002 NOV 16 BLOOD 100(11):209A-209A Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). | 0 | 2 |
2225 | 0 | 0 | 2073 2002 NOV 16 BLOOD 100(11):210A-210A Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M). | 0 | 0 |
2226 | 0 | 0 | 2074 2002 NOV 16 BLOOD 100(11):211A-211A Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. | 0 | 3 |
2227 | 0 | 0 | 2075 2002 NOV 16 BLOOD 100(11):211A-211A Myers B; Jones SG; McMillan AK; Dolan G Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. | 0 | 0 |
2228 | 0 | 0 | 2076 2002 NOV 16 BLOOD 100(11):265B-265B Manson SD; Gregory SA; Rogers K; Raza A; Loew J; Hsu WT; Sivaraman S; Venugopal P Thalidomide as a single agent leads to meaningful responses in older patients with poor prognosis acute myeloid leukemia (PP-AML) | 0 | 0 |
2229 | 0 | 0 | 2077 2002 NOV 16 BLOOD 100(11):314B-314B Hayashi T; Anderson KC; Steven SP Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. | 0 | 1 |
2230 | 0 | 0 | 2078 2002 NOV 16 BLOOD 100(11):336B-336B Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM Does thalidomide act with different mechanisms of action in myelodysplastic syndromes? | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2231 | 0 | 0 | 2079 2002 NOV 16 BLOOD 100(11):337B-337B Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes. | 0 | 0 |
2232 | 0 | 0 | 2080 2002 NOV 16 BLOOD 100(11):340B-340B Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Bellak DJ; Gezer S; Venugopal P Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS). | 0 | 2 |
2233 | 0 | 0 | 2081 2002 NOV 16 BLOOD 100(11):341B-341B Islam A; Bielat K; Smith G Does thalidomide have an effect other than anti-angiogenesis. | 0 | 0 |
2234 | 0 | 0 | 2082 2002 NOV 16 BLOOD 100(11):346B-346B Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. | 0 | 1 |
2235 | 0 | 0 | 2083 2002 NOV 16 BLOOD 100(11):367B-367B Luo SK; Li J; Hong WD; Zhou ZH Immunoreactivity of thalidomide in patients with multiple myeloma. | 0 | 0 |
2236 | 0 | 0 | 2084 2002 NOV 16 BLOOD 100(11):371B-371B Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes. | 0 | 0 |
2237 | 0 | 0 | 2085 2002 NOV 16 BLOOD 100(11):375A-375A Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients. | 0 | 0 |
2238 | 0 | 0 | 2086 2002 NOV 16 BLOOD 100(11):377B-377B Lincz LF; Enno A Thalidomide induced alterations in multiple myeloma cell surface receptor expression do not affect adhesion to bone marrow stroma or correlate with VEGF secretion in vitro. | 0 | 0 |
2239 | 0 | 0 | 2087 2002 NOV 16 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
2240 | 0 | 0 | 2088 2002 NOV 16 BLOOD 100(11):384B-384B Devabhaktuni YD; Laber DA Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2241 | 0 | 0 | 2089 2002 NOV 16 BLOOD 100(11):384B-384B Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia. | 0 | 0 |
2242 | 0 | 0 | 2090 2002 NOV 16 BLOOD 100(11):384B-384B Fawaz A; Magro L; Leleu X; Depil S; Guillerm G; Corm S; Bauters F; Facon T; Yakoub-Agha I Impact of thalidomide on survival of patients with multiple myeloma. | 0 | 2 |
2243 | 0 | 0 | 2091 2002 NOV 16 BLOOD 100(11):385B-385B Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S Thalidomide induced neuropathy in patients treated for multiple myeloma. | 0 | 0 |
2244 | 0 | 0 | 2092 2002 NOV 16 BLOOD 100(11):387B-387B Helgason HH; Smit WM; de Groot MR; Schenkeveld CEI; Neef C; Schaafsma MR Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide. | 0 | 0 |
2245 | 0 | 0 | 2093 2002 NOV 16 BLOOD 100(11):387B-387B Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M Toxicity of thalidomide in multiple myeloma patients (long-term observations). | 0 | 0 |
2246 | 0 | 0 | 2094 2002 NOV 16 BLOOD 100(11):387B-387B Meng HT; Jin J; Mai WY Thalidomide plus M2 chemotherapy in the treatment of refractory multiple myeloma. | 0 | 0 |
2247 | 0 | 0 | 2095 2002 NOV 16 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
2248 | 0 | 0 | 2096 2002 NOV 16 BLOOD 100(11):389B-389B Keyzner A; Kumar A; Besa EC The role of thalidomide and pamidronate in maintenance of plateau phase after second and third induction therapy in relapsed multiple myeloma patients. | 0 | 0 |
2249 | 0 | 0 | 2097 2002 NOV 16 BLOOD 100(11):389B-389B Huang JW; Wang YH; Du HP; Zhang J Thalidomide combined with conventional melphalan and predisone regimen for treatment of mulitiple myeloma | 0 | 0 |
2250 | 0 | 0 | 2098 2002 NOV 16 BLOOD 100(11):390B-390B Sidra GM; Russell N; Byrne J; Myers B; Mitchell D Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2251 | 0 | 0 | 2099 2002 NOV 16 BLOOD 100(11):390B-390B Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients. | 0 | 0 |
2252 | 0 | 0 | 2100 2002 NOV 16 BLOOD 100(11):390B-390B Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration. | 0 | 0 |
2253 | 0 | 0 | 2101 2002 NOV 16 BLOOD 100(11):390B-390B Sato N; Kakimoto T; Hattori Y; Okamoto S; Morita K; Tanigawara Y; Ikeda Y Thalidomide induced severe neutropenia during the treatment of multiple myeloma via direct suppression of bone marrow hematopoiesis. | 0 | 0 |
2254 | 0 | 0 | 2102 2002 NOV 16 BLOOD 100(11):392B-392B Kazmi MA; Cuadrado MJ; Karim MY; Jones RJ; Khamashta MA; Schey SA Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent. | 0 | 0 |
2255 | 0 | 0 | 2103 2002 NOV 16 BLOOD 100(11):393B-393B Moehler TM; Schlenzka J; Kasper B; Neben K; Egerer G; Ho AD; Goldschmidt H Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. | 0 | 0 |
2256 | 0 | 0 | 2104 2002 NOV 16 BLOOD 100(11):393A-393A Bahlis NJ; Sawney R; Gerson S PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines. | 0 | 0 |
2257 | 0 | 0 | 2105 2002 NOV 16 BLOOD 100(11):394A-395A Minnema MM; Fijnheer R; De Groot PG; Lokhorst HM Factor VIII procoagulant activity as risk factor for deep venous thrombosis in patients with Multiple Myeloma during treatment with thalidomide. | 0 | 0 |
2258 | 0 | 0 | 2106 2002 NOV 16 BLOOD 100(11):397A-397A Palladini G; Perfetti V; Obici L; Merlini G Thalidomide toxicity in patients with AL (primary) amyloidosis. | 0 | 3 |
2259 | 0 | 0 | 2107 2002 NOV 16 BLOOD 100(11):398A-398A Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH). | 0 | 2 |
2260 | 0 | 0 | 2108 2002 NOV 16 BLOOD 100(11):398A-398A Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis. | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2261 | 0 | 0 | 2109 2002 NOV 16 BLOOD 100(11):401A-402A Prince M; Mileshkin L; Biagi JJ; Smith JG; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Simmons PJ; Zeldis JB A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age. | 0 | 0 |
2262 | 0 | 0 | 2110 2002 NOV 16 BLOOD 100(11):402A-402A Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. | 0 | 2 |
2263 | 0 | 0 | 2111 2002 NOV 16 BLOOD 100(11):402A-403A Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial. | 0 | 1 |
2264 | 0 | 0 | 2112 2002 NOV 16 BLOOD 100(11):403A-403A Hussein MA; Elson P; Tsoe EA; Karam M; Srkaloci G Doxil (D), vincristine (V), decadron (D) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). | 0 | 4 |
2265 | 0 | 0 | 2113 2002 NOV 16 BLOOD 100(11):403A-404A Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer S; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. | 0 | 0 |
2266 | 0 | 0 | 2114 2002 NOV 16 BLOOD 100(11):426B-426B Santos E; Goodman M; Byrnes JJ; Fernandez HF Thalidomide as maintenance therapy in the post-transplantation setting in patients with multiple myeloma. | 0 | 0 |
2267 | 0 | 0 | 2115 2002 NOV 16 BLOOD 100(11):434A-434A Ghobrial IM; Kumar S; Porrata LF; Gertz MA; Gastineau DA; Ansell SM; Lacy MQ; Rajkumar VS; Micallef IN; Tefferi A; Dispenzieri A; Inwards D; Litzow MR; Markovic SN Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in Multiple Myeloma. | 0 | 0 |
2268 | 0 | 0 | 2116 2002 NOV 16 BLOOD 100(11):477B-477B Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). | 0 | 0 |
2269 | 0 | 0 | 2117 2002 NOV 16 BLOOD 100(11):671A-671A LeBlanc R; Hideshima T; Hayashi T; Catley LP; Burger R; Shringarpure R; Cheema P; Richardson P; Anderson KC; Munshi NC Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. | 0 | 0 |
2270 | 0 | 0 | 2118 2002 NOV 16 BLOOD 100(11):795A-795A Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Patkar S; Khan T; Rizvi A; Venugopal P; Gezer S; Mundle SD; Reddy PL Trilineage responses to arsenic trioxide (Trisenox (R)) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2). | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2271 | 0 | 0 | 2119 2002 NOV 16 BLOOD 100(11):800A-800A Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies. | 0 | 0 |
2272 | 0 | 0 | 2120 2002 NOV 16 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
2273 | 0 | 0 | 2121 2002 NOV 16 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
2274 | 0 | 0 | 2122 2002 NOV 16 BLOOD 100(11):813A-813A Richardson P; Jagannath S; Schlossman R; Alsina M; Desikan RK; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Dalton W; Anderson KC Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity. | 0 | 0 |
2275 | 0 | 0 | 2123 2002 NOV 16 BLOOD 100(11):815A-815A Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. | 0 | 1 |
2276 | 0 | 0 | 2124 2002 NOV 16 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
2277 | 11 | 20 | 2260 2002 20021121-03:05:49 [NOV 21] LEUKEMIA & LYMPHOMA 43(12):2301-2307 Giovanni B; Michelle E; Letizia C; Filippo B; Paolo PP; Giuseppe V; Monia M; Gabriele P; Francesca Z; Ayalew T Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies | 0 | 0 |
2278 | 7 | 11 | 2017 2002 NOV 22 AIDS 16(17):2355-2356 Teo S; Noormohamed F; Youle M; Johnson M; Peters B; Stirling D; Thomas S Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing | 1 | 1 |
2279 | 5 | 5 | 2146 2002 NOV 23 BRITISH MEDICAL JOURNAL 325(7374):1245-1245 Ashby J; Tinwell H Thalidomide is not a human mutagen | 0 | 0 |
2280 | 19 | 51 | 2152 2002 20021129-15:19:17 [NOV 29] CANCER INVESTIGATION 20(7-8):1051-1058 Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M Thalidomide in multiple myeloma-from the clinic to the laboratory | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2281 | 26 | 39 | 2125 2002 DEC 1 BLOOD 100(12):4162-4168 Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J Antimyeloma efficacy of thalidomide in the SCID-hu model | 1 | 6 |
2282 | 8 | 26 | 2020 2002 DEC [15] ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(12):2115-2122 Ginsburg PM; Ehrenpreis ED A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis | 0 | 1 |
2283 | 34 | 59 | 2126 2002 DEC [15] BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
2284 | 6 | 7 | 2142 2002 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 119(3):883-884 Gonzalez-Porras JR; Gonzalez M; Garcia-Sanz R; San Miguel JF Thalidomide in combination with cyclophosphamide and dexamethasone (ThaCyDex) is effective in soft-tissue plasmacytomas | 0 | 0 |
2285 | 0 | 2 | 2145 2002 DEC [15] BRITISH JOURNAL OF PHARMACOLOGY 137 Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse | 0 | 0 |
2286 | 7 | 10 | 2246 2002 DEC [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
2287 | 0 | 0 | 2252 2002 DEC [15] LANCET ONCOLOGY 3(12):711-711 Lindsey H Thalidomide plus dexamethasone for newly diagnosed myeloma | 0 | 0 |
2288 | 2 | 4 | 2263 2002 DEC [15] MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Crawford CL Thalidomide-induced neuropathy | 1 | 1 |
2289 | 2 | 2 | 2264 2002 DEC [15] MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Rajkumar SV; Gertz MA; Kyle RA; Greipp PR Thalidomide-induced neuropathy - In reply | 0 | 0 |
2290 | 5 | 31 | 2287 2002 DEC [15] SEMINARS IN ONCOLOGY 29(6):34-38 Durie BGM Low-dose thalidomide in myeloma: Efficacy and biologic significance | 5 | 7 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2291 | 21 | 29 | 2270 2002 DEC 24 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 6 | 7 |
2292 | 7 | 22 | 2476 2003 JAN 1 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 29 | 55 |
2293 | 7 | 10 | 2537 2003 JAN 14 NEUROLOGY 60(1):130-132 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips PC Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 | 1 | 2 |
2294 | 1 | 6 | 2300 2003 JAN [15] AMERICAN JOURNAL OF GASTROENTEROLOGY 98(1):221-222 Shurafa M; Kamboj G Thalidomide for the treatment of bleeding angiodysplasias | 1 | 2 |
2295 | 11 | 30 | 2324 2003 JAN [15] ARCHIVES OF DERMATOLOGY 139(1):50-54 Housman TS; Jorizzo JL; McCarty MA; Grummer SE; Fleischer AB; Sutej PG Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | 2 | 3 |
2296 | 19 | 50 | 2412 2003 JAN [15] BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 12 | 15 |
2297 | 44 | 59 | 2445 2003 JAN [15] CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
2298 | 5 | 41 | 2470 2003 JAN [15] INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
2299 | 9 | 42 | 2487 2003 JAN [15] JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
2300 | 8 | 17 | 2515 2003 JAN [15] LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 7 | 16 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2301 | 23 | 39 | 2532 2003 JAN [15] MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 20 |
2302 | 22 | 28 | 2428 2003 FEB 1 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 6 | 13 |
2303 | 0 | 0 | 2503 2003 FEB 1 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
2304 | 3 | 29 | 2495 2003 FEB 5 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
2305 | 77 | 104 | 2562 2003 FEB 8 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
2306 | 16 | 25 | 2325 2003 FEB [15] ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
2307 | 0 | 0 | 2441 2003 FEB [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
2308 | 166 | 221 | 2442 2003 FEB [15] CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 5 |
2309 | 0 | 0 | 2508 2003 FEB [15] LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
2310 | 59 | 70 | 2475 2003 FEB 25 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2311 | 5 | 34 | 2425 2003 MAR 1 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 1 | 5 |
2312 | 4 | 7 | 2538 2003 MAR 11 NEUROLOGY 60(5):877-878 Giannini F; Volpi N; Rossi S; Passero S; Fimiani M; Cerase A Thalidomide-induced neuropathy: a ganglionopathy? | 3 | 3 |
2313 | 0 | 0 | 2292 2003 MAR [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U196-U197 Hu ZG; Pandit B; Shi JD; Zink J; Sackett DL; Li PK Thalidomide analogs with antiproliferative and antimicrotubule activities. | 0 | 0 |
2314 | 0 | 0 | 2293 2003 MAR [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U197-U197 Luzzio FA; Ng SSW; Gutschow M; Hauschildt S; Weiss M; Teubert U; Kruger E; Mayorov AV; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogs. | 0 | 0 |
2315 | 11 | 28 | 2298 2003 MAR [15] ALIMENTARY PHARMACOLOGY & THERAPEUTICS 17(5):677-682 Khan ZH; Simpson EJ; Cole AT; Holt M; MacDonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass | 0 | 1 |
2316 | 9 | 9 | 2314 2003 MAR [15] ANNALS OF ONCOLOGY 14(3):501-502 Trojan A; Chasse E; Gay B; Pichert G; Taverna C Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma | 2 | 2 |
2317 | 0 | 0 | 2398 2003 MAR [15] BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
2318 | 0 | 0 | 2399 2003 MAR [15] BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
2319 | 4 | 9 | 2408 2003 MAR [15] BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
2320 | 4 | 12 | 2433 2003 MAR-APR [MAR 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2321 | 16 | 25 | 2438 2003 MAR [15] CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 4 | 8 |
2322 | 9 | 21 | 2439 2003 MAR [15] CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
2323 | 1 | 6 | 2454 2003 MAR [15] EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
2324 | 19 | 40 | 2486 2003 MAR 15 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
2325 | 6 | 10 | 2504 2003 MAR [15] JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 1 | 1 |
2326 | 8 | 21 | 2505 2003 MAR [15] JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):445-449 Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment | 2 | 2 |
2327 | 15 | 21 | 2547 2003 MAR [15] PHARMACOTHERAPY 23(3):315-318 Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer | 3 | 4 |
2328 | 73 | 77 | 2550 2003 MAR [15] POSTGRADUATE MEDICAL JOURNAL 79(929):127-132 Gordon JN; Goggin PM Thalidomide and its derivatives: emerging from the wilderness | 0 | 3 |
2329 | 8 | 12 | 2561 2003 MAR-APR [MAR 15] SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 16(2):123-129 Hadgraft J; Goosen C; du Plessis J; Flynn G Predicting the dermal absorption of thalidomide and its derivatives | 0 | 0 |
2330 | 8 | 20 | 2407 2003 MAR 24 BRITISH JOURNAL OF CANCER 88(6):822-827 Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer | 3 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2331 | 12 | 13 | 2524 2003 20030326-05:22:21 [MAR 26] LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
2332 | 1 | 6 | 2525 2003 20030326-05:22:21 [MAR 26] LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
2333 | 15 | 47 | 2338 2003 APR 1 BLOOD 101(7):2534-2541 Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder GE; Reeder T; Zeldis JB; Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | 5 | 8 |
2334 | 0 | 0 | 2457 2003 APR 14 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
2335 | 6 | 6 | 2308 2003 APR [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(4):489-489 Schmutz JL; Barbaud A; Trechot P Thalidomide and thrombosis | 0 | 0 |
2336 | 2 | 5 | 2311 2003 APR [15] ANNALS OF HEMATOLOGY 82(4):262-262 Ribatti A; Vacca A On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma | 0 | 0 |
2337 | 10 | 33 | 2315 2003 APR [15] ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
2338 | 0 | 0 | 2337 2003 APR [15] BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
2339 | 5 | 12 | 2413 2003 APR [15] BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 3 | 5 |
2340 | 3 | 5 | 2414 2003 APR [15] BRITISH JOURNAL OF HAEMATOLOGY 121(1):191-192 Younis TH Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2341 | 2 | 3 | 2447 2003 APR [15] DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
2342 | 21 | 37 | 2449 2003 APR [15] DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
2343 | 0 | 0 | 2458 2003 APR [15] GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
2344 | 0 | 0 | 2459 2003 APR [15] GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
2345 | 0 | 0 | 2460 2003 APR [15] GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
2346 | 4 | 9 | 2473 2003 APR [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
2347 | 10 | 14 | 2499 2003 APR [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
2348 | 0 | 0 | 2507 2003 APR [15] JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
2349 | 12 | 32 | 2516 2003 APR [15] LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 11 | 18 |
2350 | 1 | 11 | 2533 2003 APR [15] MEDICAL HYPOTHESES 60(4):513-514 Namazi MR The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2351 | 43 | 78 | 2548 2003 APR [15] PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
2352 | 6 | 25 | 2559 2003 APR [15] SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 2 | 3 |
2353 | 7 | 29 | 2560 2003 APR [15] SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 5 |
2354 | 1 | 2 | 2534 2003 APR 21 MEDICAL JOURNAL OF AUSTRALIA 178(8):413-413 Elwood JM Thalidomide and cancer? | 0 | 0 |
2355 | 2 | 3 | 2539 2003 MAY 1 NEW ENGLAND JOURNAL OF MEDICINE 348(18):1821-1822 Morgan AE; Smith WK; Levenson JL Reversible dementia due to thalidomide therapy for multiple myeloma | 1 | 1 |
2356 | 4 | 37 | 2301 2003 MAY [15] AMERICAN JOURNAL OF HEMATOLOGY 73(1):48-53 Lee FC; Merchant SH Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide | 1 | 2 |
2357 | 12 | 27 | 2319 2003 MAY-JUN [MAY 15] ANTICANCER RESEARCH 23(3B):2405-2411 Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice | 0 | 0 |
2358 | 6 | 17 | 2320 2003 MAY-JUN [MAY 15] ANTICANCER RESEARCH 23(3B):2481-2487 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells | 0 | 0 |
2359 | 0 | 4 | 2328 2003 MAY [15] ARCHIVOS DE BRONCONEUMOLOGIA 39(5):240-240 Garcia BD; Gafas AD; Alvarez MJF Lung toxicity due to thalidomide | 0 | 0 |
2360 | 5 | 11 | 2409 2003 MAY [15] BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2361 | 30 | 38 | 2434 2003 MAY [15] CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 5 | 6 |
2362 | 0 | 0 | 2452 2003 MAY [15] EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
2363 | 3 | 10 | 2461 2003 MAY [15] HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
2364 | 12 | 39 | 2467 2003 MAY [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
2365 | 9 | 12 | 2500 2003 MAY [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
2366 | 11 | 52 | 2501 2003 MAY-JUN [MAY 15] JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
2367 | 45 | 67 | 2542 2003 MAY [15] ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 95(5):576-585 Hegarty A; Hodgson T; Porter S Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis | 1 | 2 |
2368 | 4 | 19 | 2563 2003 20030527-21:08:57 [MAY 27] SYNTHETIC COMMUNICATIONS 33(8):1375-1382 Chang MY; Chen ST; Chang NC A synthesis of racemic thalidomide | 0 | 4 |
2369 | 6 | 15 | 2477 2003 JUN 1 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
2370 | 5 | 9 | 2295 2003 20030604-09:41:54 [JUN 04] ACTA HAEMATOLOGICA 109(3):153-155 Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL Thalidomide administration for the treatment of resistant plasma cell leukemia | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2371 | 22 | 30 | 2318 2003 JUN [15] ANTI-CANCER DRUGS 14(5):331-335 Dredge K; Dalgleish AG; Marriott JB Thalidomide analogs as emerging anti-cancer drugs | 2 | 6 |
2372 | 1 | 5 | 2329 2003 JUN [15] ARCHIVOS DE BRONCONEUMOLOGIA 39(6):286-286 Valero FC Lung toxicity due to thalidomide | 0 | 0 |
2373 | 2 | 6 | 2400 2003 JUN [15] BONE MARROW TRANSPLANTATION 31(11):1065-1065 Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 0 | 0 |
2374 | 0 | 1 | 2401 2003 JUN [15] BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
2375 | 4 | 12 | 2415 2003 JUN [15] BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
2376 | 21 | 31 | 2429 2003 JUN 15 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 3 | 5 |
2377 | 5 | 20 | 2440 2003 JUN [15] CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 1 | 4 |
2378 | 7 | 20 | 2469 2003 JUN [15] INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
2379 | 4 | 37 | 2478 2003 JUN 15 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 0 | 3 |
2380 | 9 | 39 | 2496 2003 JUN [15] JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2381 | 5 | 8 | 2517 2003 JUN [15] LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
2382 | 43 | 95 | 2553 2003 JUN [15] SCHMERZ 17(3):204-+ Peuckmann V; Strumpf M; Zenz M; Bruera E Novel potential uses of thalidomide in the management of pain? A review of the literature | 0 | 0 |
2383 | 11 | 18 | 2446 2003 20030620-19:10:16 [JUN 20] DERMATOLOGY 206(4):381-383 Kolivras A; De Maubeuge J; Andre J; Song M Thalidomide in refractory vulvar ulcerations associated with Crohn's disease | 1 | 1 |
2384 | 2 | 7 | 2326 2003 JUN 23 ARCHIVES OF INTERNAL MEDICINE 163(12):1487-1488 Schwartzman R; Chevlen E; Bengtson K Thalidomide has activity in treating complex regional pain syndrome | 0 | 0 |
2385 | 1 | 1 | 2327 2003 JUN 23 ARCHIVES OF INTERNAL MEDICINE 163(12):1488-1488 Rajkumar SV; Fonseca R; Witzig TE Thalidomide has activity in treating complex regional pain syndrome - Reply | 0 | 0 |
2386 | 52 | 86 | 2443 2003 JUN 27 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 0 | 1 |
2387 | 13 | 38 | 2444 2003 JUN 27 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
2388 | 0 | 4 | 2339 2003 JUL 1 BLOOD 102(1):2-3 Hussein MA Thalidomide, age, and future use in multiple myeloma | 0 | 0 |
2389 | 18 | 42 | 2340 2003 JUL 1 BLOOD 102(1):69-77 Mileshkin L; Biagi JJ; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Lillie K; Smith JG; Zeldis JB; Prince HM Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age | 7 | 10 |
2390 | 5 | 37 | 2479 2003 JUL 1 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 0 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
2391 | 7 | 17 | 2322 2003 20030710-02:00:52 [JUL 10] APMIS 111:113-116 Chew M; Zhou J; Daugherty A; Eriksson T; Ellermann-Eriksen S; Hansen PR; Falk E Thalidomide inhibits early atherogenesis in apoE-deficient mice | 0 | 0 |
2392 | 8 | 19 | 2316 2003 JUL-AUG [JUL 15] ANNALS OF PHARMACOTHERAPY 37(7-8):1040-1043 Kaur A; Yu SS; Lee AJ; Chiao TB Thalidomide-induced sinus bradycardia | 1 | 1 |
2393 | 13 | 35 | 2402 2003 JUL [15] BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 0 | 1 |
2394 | 0 | 0 | 2405 2003 JUL [15] BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
2395 | 0 | 0 | 2406 2003 JUL [15] BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
2396 | 0 | 0 | 2410 2003 JUL [15] BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
2397 | 4 | 7 | 2416 2003 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 1 | 1 |
2398 | 5 | 6 | 2417 2003 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 122(1):160-161 Harris E; Behrens J; Samson D; Rahemtulla A; Russell NH; Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia | 2 | 3 |
2399 | 5 | 27 | 2426 2003 JUL [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
2400 | 0 | 0 | 2455 2003 JUL [15] EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
Page 8: 1 2 3 4 5 6 7 8 9
Generated by:
HistCite(Vlad).
Version: 2004.09.22